Anderson-Fabry disease: An important differential diagnosis in patients with unexplained left ventricular hypertrophy

Heart and Metabolism

Volumn , Issue 33, 2006, Pages 25-29

  Elliott, Perry ^a,b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

Author keywords

Anderson Fabry disease; Left ventricular hypertrophy; Women

Indexed keywords

AGALSIDASE ALFA; ALPHA GALACTOSIDASE;

AMINO ACID SUBSTITUTION; ANAMNESIS; ARTICLE; CASE REPORT; CLINICAL FEATURE; DIFFERENTIAL DIAGNOSIS; ELECTROCARDIOGRAPHY; FABRY DISEASE; FEMALE; GENE MUTATION; GENETIC ANALYSIS; HEART LEFT VENTRICLE HYPERTROPHY; HETEROZYGOTE; HUMAN; PHYSICAL EXAMINATION; PRIORITY JOURNAL;

EID: 33846100966     PISSN: 15660338     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Desnick RJ, Ioannou YA, Eng CM. α-Galactosidase A deficiency: Fabry disease. In: The Metabolic and Molecular Bases of Inherited Disease, 8th edn. Edited by Scriver CR, Beaudet AL, Sly WS, Valle D. New York: McGraw-Hill; 2001. pp. 3733-3774.
2. Mehta A, Ricci R, Widmer U, et al. Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey. Eur J Clin Invest. 2004;34:236-242.
3. MacDermot KD, Holmes A, Miners AH. Anderson-Fabry disease Clinical manifestations and impact of disease in a cohort of 60 obligate carrier females. J Med Genet. 2001;38:769-775.
4. MacDermot KD, Holmes A, Miners AH. Anderson-Fabry disease Clinical manifestations and impact of disease in a cohort of 98 hemizygous males. J Med Genet.2001;38:750-760.
5. Spada M, Pagliardini S, Yasuda M, et al. High incidence of later-onset Fabry disease revealed by newborn screening. Am J Hum Genet. 2006;79:31-40.
6. Kotanko P, Kramar R, Devrnja D, et al. Results of a nationwide screening for Anderson-Fabry disease among dialysis patients. J Am Soc Nephrol. 2004;15:1323-1329.
7. Rolfs A, Böttcher T, Zschiesche M, et al. Prevalence of Fabry disease in patients with cryptogenic stroke: a prospective study. Lancet. 2005;366:1794-1796.
8. Nakao S, Takenaka T, Maeda M, et al. An atypical variant of Fabry's disease in men with left ventricular hypertrophy. N Engl J Med. 1995;333:288-293.
9. Sachdev B, Takenaka T, Teraguchi H, et al. Prevalence of Anderson-Fabry disease in male patients with late onset hypertrophic cardiomyopathy. Circulation. 2002;105:1407-1411.
10. Chimenti C, Pieroni M, Morgante E, et al. Prevalence of Fabry disease in female patients with late-onset hypertrophic cardiomyopathy. Circulation. 2004;110:1047-1053.
11. Dobrovolny R, Dvorakova L, Ledvinova J, et al. Relationship between X-inactivation and clinical involvement in Fabry heterozygotes. Eleven novel mutations in the α-galactosidase A gene in the Czech and Slovak population. J Mol Med. 2005;3:647-654.
12. Garman SC, Garboczi DN. Structural basis of Fabry disease. Mol Genet Metab. 2002;77:3-11.
13. Pastores GM, Lien Y. Bicohemical and molecular basis of Fabry disease. J Am Soc Nephrol. 2002;13:S130-S133.
14. Eng CM, Resnick-Silverman LA, Niehaus DJ, Astrin KH, Desnick RJ. Nature and frequency of mutations in the alpha-galactosidase A gene that cause Fabry disease. Am J Hum Genet. 1993;53:1186-1197.
15. Desnick RJ, Schuchman EH. Enzyme therapy and enhancement therapies: lessons from lysosomal disorders. Nature. 2002;3:954-966.
16. Redonnet-Vernhet I, Ploos van Amstel JK, Jansen RPM, et al. Uneven X inactivation in a female monozygotic twin pair with Fabry disease and discordant expression of a novel mutation in the alpha-galactosidase A gene. J Med Genet. 1996;33:682-688.
17. Schiffmann R, Kopp JB, Austin HA 3rd, et al. Enzyme replacement therapy in Fabry disease: a randomized controlled trial. JAMA. 2001;285:2743-2749.
18. Eng CM, Guffon N, Wilcox WR, et al., for the International Collaborative Fabry Disease Study Group. Safety and efficacy of recombinant human alpha-galactosidase A - replacement therapy in Fabry's disease. N Engl J Med. 2001;345:9-16.
19. Beck M, Ricci R, Widmer U, et al. Fabry disease: overall effects of agalsidase alfa treatment. Eur J Clin Invest. 2004;34:838-844.
20. Schiffmann R, Floeter MK, Dambrosia JM, et al. Enzyme replacement therapy improves peripheral nerve and sweat function in Fabry disease. Muscle Nerve. 2003;28:703-710.
21. Moore DF, Altarescu G, Ling GS, et al. Elevated cerebral blood flow velocities in Fabry disease with reversal after enzyme replacement. Stroke. 2002;33:525-531.
22. Weidemann F, Breunig F, Beer M, et al. Improvement of cardiac function during enzyme replacement therapy in patients with Fabry disease: a prospective strain rate imaging study. Circulation. 2003;108:1299-1301.
23. Spinelli L, Pisani A, Sabbatini M, et al. Enzyme replacement therapy with agalsidase beta improves cardiac involvement in Fabry's disease. Clin Genet. 2004;66:158-165.
24. Komamura K, Higashi M, Yamada N. Improvement of cardiac hypertrophy and ventricular function in a man with Fabry disease by treatment with recombinant alpha-galactosidase A. Heart. 2004;90:617.